Forecast Period | 2025-2029 |
Market Size (2023) | USD 1.15 Billion |
Market Size (2029) | USD 8.42 Billion |
CAGR (2024-2029) | 39.30% |
Fastest Growing Segment | Vitamin E And Pioglitazone Segment |
Largest Market | North America |
Market Overview
Global Non-Alcoholic Steatohepatitis Treatment
Market valued at USD 1.15 billion in 2023 and is anticipated to project
robust growth in the forecast period with a CAGR of 39.30% through 2029.
Non-Alcoholic Steatohepatitis Treatment is to prevent the progression of the
disease and to reduce the associated liver inflammation and damage. NASH is a
more advanced form of non-alcoholic fatty liver disease (NAFLD), characterized
by inflammation and liver cell injury. If left untreated, NASH can lead to more
serious liver conditions, such as fibrosis (scarring), cirrhosis (advanced
scarring), and even liver failure. Additionally, NASH increases the risk of
other complications like cardiovascular disease and diabetes, and increased
awareness of the health benefits associated with Non-Alcoholic Steatohepatitis
Treatment are expected to positively influence the global market growth.
The primary aim of NASH treatment is to reduce the
inflammation and injury occurring in the liver. This helps to slow down or halt
the progression of the disease to more severe stages, such as fibrosis and
cirrhosis. Fibrosis is the accumulation of scar tissue in the liver, and
cirrhosis is the advanced stage of scarring. NASH treatment aims to prevent or
minimize the development of fibrosis and cirrhosis, as these conditions can
lead to significant liver dysfunction and complications. Many individuals with
NASH also have insulin resistance and are at risk of developing type 2
diabetes. NASH treatment often includes interventions to improve insulin
sensitivity, which can help reduce liver inflammation and the accumulation of
fat in the liver. Weight loss is a key component of NASH treatment, especially
in individuals who are overweight or obese. Losing excess weight can lead to
improvements in liver health, insulin sensitivity, and overall metabolic
function. NASH is closely associated with obesity, metabolic syndrome, and
related conditions like type 2 diabetes and dyslipidaemia. NASH treatment
involves managing these underlying risk factors to improve overall health and
reduce the impact on the liver.
Key Market Drivers
Rising Prevalence of Non-Alcoholic Steatohepatitis (NASH)
The rising prevalence of Non-Alcoholic
Steatohepatitis (NASH) directly contributes to the growth of the global NASH
treatment market. NASH is a progressive liver disease characterized by
inflammation and liver cell damage, often associated with obesity, insulin
resistance, and metabolic syndrome. As the prevalence of NASH increases, the
number of individuals diagnosed with the condition also rises. This larger
patient population creates a greater demand for effective treatments and
therapies to manage the disease. With greater awareness and understanding of
NASH among both healthcare professionals and the general population, more cases
are being diagnosed. Improved diagnostic methods and guidelines have
contributed to earlier and more accurate detection of NASH, leading to
increased demand for treatment options. The economic burden of NASH on
healthcare systems is substantial due to its potential to progress to advanced
liver conditions like fibrosis, cirrhosis, and hepatocellular carcinoma. This
drives healthcare providers, governments, and patients to invest in appropriate
treatment strategies to prevent disease progression and associated
complications.
NASH can lead to a reduced quality of life due to
symptoms like fatigue, discomfort, and the psychological impact of a chronic
liver condition. Patients are motivated to seek treatment to improve their
overall well-being and maintain a higher quality of life. Efforts to increase
awareness about NASH, its risk factors, and its potential consequences have led
to more individuals seeking medical attention and treatment options. This
growing awareness is a key driver behind the increasing prevalence of NASH
cases. The global rise in obesity rates and the prevalence of metabolic
syndrome, which includes factors like insulin resistance and dyslipidaemia,
directly contribute to the increased risk of developing NASH. As these
conditions become more common, so does the incidence of NASH.
Lifestyle Changes and Obesity Epidemic
Lifestyle changes and the obesity epidemic play a
significant role in driving the growth of the global Non-Alcoholic
Steatohepatitis (NASH) treatment market. NASH is closely linked to obesity,
insulin resistance, and metabolic syndrome, and the increasing prevalence of
these conditions has a direct impact on the demand for NASH treatments. Obesity
is a major risk factor for the development of NASH. As the global obesity
epidemic continues, more individuals are at a higher risk of developing NASH
due to the accumulation of fat in the liver and associated metabolic
disturbances. Metabolic syndrome, a cluster of conditions including obesity,
high blood pressure, high blood sugar, and abnormal cholesterol levels, is
closely linked to NASH. The rising prevalence of metabolic syndrome contributes
to the growing incidence of NASH cases. Obesity and sedentary lifestyles are
associated with insulin resistance, a condition where the body's cells do not
respond effectively to insulin. Insulin resistance is a key factor in the
development of NASH, and its prevalence drives the demand for treatments.
Lifestyle changes, including diet modifications and
increased physical activity, are crucial components of NASH treatment. As more
individuals become aware of the connection between their lifestyle habits and
NASH risk, there is a growing demand for interventions that can help manage the
condition through lifestyle changes. Weight loss is a primary goal in NASH
treatment, as shedding excess weight can lead to improvements in liver health
and metabolic function. The obesity epidemic highlights the need for weight
management strategies, both as prevention and treatment for NASH. Efforts to
address the obesity epidemic and promote healthier lifestyles contribute to
increased awareness about NASH and its potential consequences. Public health
campaigns aimed at reducing obesity often indirectly contribute to greater
awareness of related conditions like NASH.
Increasing Healthcare Expenditure
Increasing healthcare expenditure plays a key role
in driving the growth of the global Non-Alcoholic Steatohepatitis (NASH)
treatment market. NASH is a progressive liver disease associated with obesity,
insulin resistance, and metabolic syndrome. As healthcare expenditures rise,
there is a greater focus on addressing chronic diseases like NASH, which
require ongoing medical management and treatment. With rising healthcare
expenditures, healthcare providers and policymakers recognize the economic and
healthcare burden posed by chronic diseases like NASH. This recognition drives
the need for investment in research, diagnostics, treatments, and interventions.
Increased healthcare spending often leads to improved diagnostic capabilities
and greater access to screenings for diseases like NASH. This results in more
accurate and earlier detection of NASH cases, driving the demand for
appropriate treatment options. Investments in advanced diagnostic technologies,
such as imaging techniques and blood tests, enable healthcare professionals to
better identify and monitor NASH patients. Accurate diagnosis is crucial for
tailoring effective treatment plans. Higher healthcare expenditures can support
public health campaigns and patient education initiatives focused on NASH.
Increased awareness about the disease encourages individuals to seek medical
attention and treatment, contributing to market growth.
Greater healthcare funding can support research
efforts to understand the underlying mechanisms of NASH and develop innovative
treatments. Pharmaceutical companies receive more financial support for
conducting clinical trials and developing new therapies. Increased healthcare
spending can lead to improved access to healthcare services, medications, and
treatments, making NASH treatments more available and accessible to patients in
need. Expanding healthcare infrastructure can facilitate the management of
chronic diseases like NASH. This includes the availability of specialized
clinics, medical professionals, and resources dedicated to NASH diagnosis and
treatment.
Download Free Sample Report
Key Market Challenges
Limited Understanding of Disease Mechanisms
The limited understanding of disease mechanisms
poses a significant challenge for the global Non-Alcoholic Steatohepatitis
(NASH) treatment market. NASH is a complex liver disease characterized by
inflammation and liver cell damage, often associated with obesity, insulin
resistance, and metabolic syndrome.
Without a comprehensive understanding of the
underlying mechanisms driving NASH, it's difficult to develop targeted
therapies that address the specific pathways responsible for the disease's
development and progression. This can result in a lack of effective treatment
options. The diverse nature of NASH, which includes varying degrees of
inflammation, fibrosis, and metabolic dysfunction, leads to heterogeneity in
patient responses to treatments. A deeper understanding of disease mechanisms
could help identify subtypes of NASH and guide personalized treatment
approaches.
Developing therapies without a complete
understanding of NASH's underlying biology may inadvertently trigger unintended
consequences or side effects. This could delay treatment development or even
worsen patient outcomes. The lack of clarity about disease mechanisms can
extend the drug development process. Researchers may need to conduct more
exploratory studies to identify potential therapeutic targets, which can
prolong the timeline for bringing new treatments to market. Clinical trials for
NASH therapies may have a higher risk of failure if the interventions are not
grounded in a deep understanding of disease mechanisms. This can result in
resources wasted on unsuccessful trials. This challenge significantly hampers
the adoption and usage of such supplements by new customers, ultimately
impacting market growth in the forecast period.
Risk of Misdiagnosis and Underdiagnosis
The risk of misdiagnosis and underdiagnosis poses a
significant challenge for the global Non-Alcoholic Steatohepatitis (NASH)
treatment market. NASH is a liver condition characterized by inflammation and
liver cell damage, often associated with obesity, insulin resistance, and metabolic
syndrome. Misdiagnosis and underdiagnosis of NASH can lead to delayed or
inadequate treatment, impacting patient outcomes and the overall growth of the
treatment market. NASH can be asymptomatic, especially in its early stages.
Patients may not experience noticeable symptoms, leading to a lack of awareness
and delaying diagnosis. This makes it challenging to identify and treat NASH
before it progresses to more severe stages.
The symptoms of NASH can overlap with those of
other liver conditions, such as alcoholic liver disease, viral hepatitis, and
even non-alcoholic fatty liver disease (NAFLD) without inflammation. This
similarity can result in misdiagnosis or confusion with other diseases. Unlike
certain conditions like diabetes or high blood pressure, routine screening for
NASH is not widespread. This means that individuals with risk factors for NASH,
such as obesity and metabolic syndrome, might not be tested for the disease,
leading to underdiagnosis.
Lack of Non-Invasive Diagnostic Tools
The lack of non-invasive diagnostic tools poses a
significant challenge for the global Non-Alcoholic Steatohepatitis (NASH)
treatment market. NASH is a liver disease characterized by inflammation and
liver cell damage, often associated with obesity, insulin resistance, and
metabolic syndrome. Non-invasive diagnostic tools are crucial for accurately
diagnosing NASH, assessing disease severity, and monitoring treatment response.
liver biopsy is considered the gold standard for diagnosing NASH and evaluating
liver fibrosis. However, liver biopsy is an invasive procedure that carries
risks, discomfort, and potential complications. Patients and healthcare
providers are often hesitant to undergo or recommend liver biopsies due to
these factors. Due to the invasive nature of liver biopsy, some patients may be
unwilling to undergo the procedure, leading to missed opportunities for
diagnosis and disease monitoring. This lack of patient compliance can hinder
timely intervention and treatment.
The reliance on liver biopsy can lead to
underdiagnosis or misdiagnosis of NASH, especially in cases where patients are
unwilling to undergo the procedure. This can result in delayed or inadequate
treatment. The lack of non-invasive diagnostic tools limits clinicians' ability
to accurately diagnose NASH, assess disease severity, and determine appropriate
treatment strategies. This unmet need hampers the development of individualized
patient care plans.
Key Market Trends
Rise in Clinical Trials
The rise in clinical trials is a significant trend in
the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market. Clinical
trials play a pivotal role in advancing our understanding of NASH, evaluating
the safety and efficacy of potential treatments, and contributing to the
development of novel therapies. The NASH landscape lacks FDA-approved
medications as of my last update in September 2021. The rise in clinical trials
indicates a growing interest in developing new therapeutic options. These
trials focus on testing various drug candidates with diverse mechanisms of
action, including targeting inflammation, fibrosis, metabolism, and other
pathways associated with NASH. Clinical trials provide a platform to validate
the potential of drug candidates. These trials assess the safety, efficacy, and
tolerability of investigational medications under controlled conditions.
Positive trial results can lead to regulatory approvals and the introduction of
new therapies to the market.
The increasing number of clinical trials indicates
a robust pipeline of potential NASH treatments. This pipeline diversity
includes different drug classes, combination therapies, and interventions aimed
at addressing various disease aspects. A vibrant pipeline reflects the
commitment of pharmaceutical companies and researchers to addressing NASH's
unmet medical need. Clinical trials contribute to a deeper understanding of
NASH's pathophysiology and its response to different interventions. Trials
generate valuable data on disease progression, biomarkers, and patient
populations, which inform the development of targeted treatments. Clinical
trials provide patients with access to innovative therapies and specialized
care. Patient participation helps researchers collect critical data, enabling
them to refine treatment approaches and gain insights into patient experiences
and preferences.
Segmental Insights
Drug Type Insights
Based on the category of Drug Type, the Vitamin E
and pioglitazone segment emerged as the dominant player in the global market
for Non-Alcoholic Steatohepatitis Treatment in 2023. Vitamin
E and pioglitazone were among the drug types explored for the treatment of
Non-Alcoholic Steatohepatitis (NASH). Please note that the landscape of NASH
treatment is dynamic and constantly evolving.
The Vitamin
E is an antioxidant that is believed to help reduce oxidative stress and
inflammation in the liver. It has been studied as a potential treatment for
NASH due to its ability to counteract oxidative damage. Clinical trials have
assessed the use of Vitamin E supplements, specifically alpha tocopherol, for
the treatment of NASH. Some trials have shown modest improvements in liver
enzymes and histological features of NASH. Vitamin E has been associated with
improvements in liver enzymes and histological features of NASH, particularly
in individuals with non-diabetic NASH. However, its effectiveness varies, and
it might not be suitable for all patient populations. The use of Vitamin E in
NASH treatment has been somewhat controversial due to concerns about potential
side effects and the variability in treatment response among different patient
groups.
Also,
the Vitamin E and pioglitazone have shown potential benefits in the treatment
of NASH, particularly in specific patient populations. However, it's important
to note that neither Vitamin E nor pioglitazone is a definitive or universally
effective treatment for NASH. The landscape of NASH treatment continues to
evolve, and ongoing research is exploring various drug classes and combination
therapies to address the complex pathophysiology of the disease. These factors are expected to drive the growth of
this segment.
Download Free Sample Report
Regional Insights
North America emerged as the dominant region in the
global Non-Alcoholic Steatohepatitis Treatment market in 2023, holding the
largest market share in terms of value. North America, particularly the United
States, has been facing a significant burden of obesity, type 2 diabetes, and
metabolic syndrome – all of which are major risk factors for NASH. The high
prevalence of these conditions contributes to a larger pool of individuals at
risk of developing NASH.
The region boasts well-developed healthcare systems,
including advanced medical facilities, specialized clinics, and access to
cutting-edge diagnostic and treatment technologies. This infrastructure
facilitates early diagnosis and comprehensive management of NASH. North America
is a hub for clinical research and pharmaceutical innovation. Many research
institutions, academic centres, and pharmaceutical companies in the region are
actively engaged in developing and testing NASH treatments. The United States
and Canada have a strong healthcare education system that raises awareness
about chronic diseases, including NASH. This heightened awareness can lead to
early detection, diagnosis, and treatment initiation. The pharmaceutical
industry in North America has shown a significant interest in NASH research and
drug development. This engagement has led to clinical trials, investments, and
collaborations to bring NASH therapies to market.
Recent Developments
- In March 2024, The U.S. Food and Drug Administration has approved resmetirom (Rezdiffra™) for the treatment of nonalcoholic steatohepatitis (NASH) in patients with stage 2 or 3 fibrosis, excluding cirrhosis. This marks the first approval of a drug for NASH in the United States. The approval is based on clinical evidence from the MAESTRO NASH trial (NCT03900429), which demonstrated that approximately 25% of patients experienced resolution of NASH and improvement in fibrosis. Resmetirom functions by activating the thyroid hormone pathway in the liver, thereby enhancing the metabolism of liver fat. This therapeutic advancement highlights a significant milestone in the management of NASH, complementing a healthy diet and regular exercise.
- In February 2024, A team of Korean researchers has developed a promising new drug candidate for treating non-alcoholic fatty liver disease (NAFLD), targeting peripheral tissues. This breakthrough addresses a critical gap in the treatment of non-alcoholic steatohepatitis (NASH), a condition for which optimal therapies have been lacking. The new drug holds significant potential to advance the development of treatments capable of effectively and safely reducing both liver fat accumulation and liver fibrosis simultaneously.
- In June 2023 - Intercept continues to plan to
submit to the FDA a regulatory submission in 2023 to support compliance with
post marketing requirements in PBC with Ocaliva. The submission will include
post marketing COBALT data and additional real-world data from large datasets
across the United States and Europe.
- In May 2023, GLMD announced today the finalization
of a USD3 million equity financing for OnKai, Inc., leading a USD6 million
investment round. The financing agreement gives Galmed a minority but strategic
interest in Onkai, while simultaneously signing a Strategic Partnership
Agreement (SPA) to drive forward the growth of both companies by capitalizing
on their shared expertise and experience.
Key Market Players
- Intercept Pharmaceuticals Inc.
- Galmed Research & Development Ltd.
- INVENTIVA S.A.
- AbbVie Inc.
- Galectin Therapeutics Inc.
- Madrigal Pharmaceuticals Inc.
- NGM Biopharmaceuticals Inc.
- Novo Nordisk A/S
- Bristol Myers Squibb
- Gilead Sciences Inc.
|
By
Drug Type
|
By
End User
|
By
Region
|
- Vitamin
E and Pioglitazone
- Obeticholic
Acid (OCA)
- Lanifibranor
- Semaglutide
- Resmetirom
- Aramchol
- Cenicriviroc
- Others
|
- Hospital
Pharmacies
- Retail
and Specialty Pharmacies
- Others
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Non-Alcoholic
Steatohepatitis Treatment Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- Non-Alcoholic
Steatohepatitis Treatment Market, By Drug Type:
o Vitamin E and Pioglitazone
o Obeticholic Acid (OCA)
o Lanifibranor
o Semaglutide
o Resmetirom
o Aramchol
o Cenicriviroc
o Others
- Non-Alcoholic
Steatohepatitis Treatment Market, By End-User:
o Hospital Pharmacies
o Retail and Specialty Pharmacies
o Others
- Non-Alcoholic
Steatohepatitis Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Non-Alcoholic Steatohepatitis Treatment Market.
Available Customizations:
Global Non-Alcoholic Steatohepatitis Treatment
market report with the given market data, TechSci Research offers customizations
according to a company's specific needs. The following customization options
are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Non-Alcoholic Steatohepatitis Treatment
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]